Skip to main content
SBHMY logo

Sino Biopharmaceutical Limited (SBHMY) Stock Price & Analysis

Sino Biopharmaceutical Limited (SBHMY) — price $14.40 (0.00%), as of the Nov 19, 2026 trading session; market cap $12.8B.

Educational signal · not a buy or sell recommendation · How to read this

$14.40 $0.00 (0.00%) Market Cap $12.8B

Sino Biopharmaceutical Limited · SBHMY · Healthcare · Medical - Pharmaceuticals

Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • ONC · BeOne Medicines Ltd. · 96 /100
  • DMRA · Galecto, Inc. · 50 /100
  • CGEM · Cullinan Therapeutics, Inc. · 51 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$14.40
Change on the day0.00%
52-week range$11.27–$19.45
Market capitalisation$12.8B—
Price / earnings (trailing)34.19
Shares traded on the day200
Beta (volatility vs the S&P 500)0.61
Dividends per share (last 12 months)$0.31
Dividend yield (last 12 months)2.13%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $11, high $19, latest $14. $19 $11 high $19 Oct 17, 2025 Nov 19, 2026 · $14 $19Oct 17, 2025$19Oct 31, 2025$19Nov 14, 2025$18Nov 28, 2025$18Dec 12, 2025$18Dec 26, 2025$18Jan 9, 2026$18Jan 23, 2026$16Feb 6, 2026$16Feb 20, 2026$16Mar 6, 2026$16Mar 20, 2026$16Apr 2, 2026$16Apr 17, 2026$14May 1, 2026$14May 15, 2026$14May 29, 2026$11Jun 12, 2026$13Jun 26, 2026$13Jul 10, 2026$13Jul 24, 2026$13Aug 7, 2026$13Aug 21, 2026$14Sep 4, 2026$15Sep 18, 2026$16Oct 2, 2026$14Oct 16, 2026$12Oct 30, 2026$14Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Sino Biopharmaceutical (SBHMY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Neutral
ROE Neutral
Gross Margin Strong

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Sino Biopharmaceutical (SBHMY), and what does it report?

Short answer

Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Healthcare / Medical Pharmaceuticals Headquarters: Unit 09, Office Tower, Hong Kong, HK. It employs 21,435 people and is led by S. Y. Tse. In Q2 FY2026 it reported revenue of CN¥9.72B and net income of CN¥1.72B. The market values it at $12.8B.

2 · Latest results

What do the latest results show for Sino Biopharmaceutical (SBHMY)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CN¥9.72B.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.23B Aug 15, 2025
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Aug 15, 2025$1.23BNot available$0.2621Not available
Mar 26, 2025$889.68MNot available$0.0018Not available
Mar 20, 2025$925.73MNot available$0.0019Not available
Aug 13, 2024$1.09BNot available$0.0113Not available
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CN¥9.72BCN¥1.72BCN¥1.90 (diluted)
Q1 FY2026CN¥9.72BCN¥1.72BCN¥1.90 (diluted)
Q4 FY2025CN¥7.13B-CN¥523M-CN¥0.58 (diluted)
Q3 FY2025CN¥7.13B-CN¥523M-CN¥0.58 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Sino Biopharmaceutical (SBHMY)?

Short answer · as of

The distress and quality screens read Altman Z 2.86 · Piotroski F 6. Trailing ratios: ROE 7.6% · ROA 2.9% · current ratio 1.63 · earnings yield 2.8% · free-cash-flow yield 6.2%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SBHMY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SBHMY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Sino Biopharmaceutical (SBHMY) — Healthcare

Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.

How do Qingkeshu and Leweixin fit Sino Biopharmaceutical’s business?

Qingkeshu tablets and Leweixin injections are oncology products within a much broader medicine portfolio. Their presence illustrates the group’s therapeutic breadth rather than defining Sino Biopharmaceutical as an oncology-only company.

What is the SBHMY stock price today?

The last price recorded for Sino Biopharmaceutical Limited (SBHMY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Does SBHMY pay a dividend?

Yes. The dividend yield of Sino Biopharmaceutical Limited (SBHMY) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 29 figures on this page — 24 from Financial Modeling Prep (FMP), 3 with no recorded source and 2 computed by us, formula shown in the register. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • FAQ: How do Qingkeshu and Leweixin fit Sino Biopharmaceutical’s business?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.